Recently posted is a new article with Mark Bacon (Spinal Research Director) in the UK explaining the current efforts in bringing a Chondroitinase human clinical trial forward. The full article can be found HERE.
Key points in the article:
1. We want to create a multidisciplinary, multinational network of experts devoted to spinal cord imaging in a way never seen before and expect to make some major announcements on this soon.
2. We are nearly there and are currently funding a number of groups to develop a clinically-acceptable version.
3. Current gene therapy technology is a bit like a light dimmer switch – we can reduce the gene expression to ‘dim’ but not completely ‘off’. The critical work we are doing now in laboratories is to create a true ‘on/off switch’.
Large-Scale Chondroitin Sulfate Proteoglycan Digestion with Chondroitinase Gene Therapy Leads to Reduced Pathology and Modulates Macrophage Phenotype following Spinal Cord Contusion Injury: ABSTRACT HERE